We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Enzyme Inhibitor Blocks Respiratory Virus Replication

By LabMedica International staff writers
Posted on 29 May 2018
Print article
Image: The novel molecule IMP-1088 (yellow) blocks human NMT (blue), a protein essential for the cold virus to assemble the geometric capsid shell, which encloses its RNA genome (green) (Photo courtesy of Imperial College London).
Image: The novel molecule IMP-1088 (yellow) blocks human NMT (blue), a protein essential for the cold virus to assemble the geometric capsid shell, which encloses its RNA genome (green) (Photo courtesy of Imperial College London).
A recently crafted drug molecule has proven to be a potential candidate for treatment of the viruses responsible for the common cold and other respiratory diseases.

Rhinoviruses (RVs) are the pathogens most often responsible for the common cold, and are a frequent cause of complications in asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

In an effort to combat respiratory viruses, investigators at Imperial College London (United Kingdom) synthesized the compound IMP-1088, a picomolar dual inhibitor of the human enzymes N-myristoyltransferases NMT1 and NMT2. N-myristoyltransferase catalyzes the transfer of myristate - a rare 14-carbon saturated fatty acid, which is attached by an amide linkage to the N-terminal glycine residue of cellular and viral proteins with diverse functions - from CoA to proteins.

Crystal structures and other evidence had revealed that two inhibitors, which the investigators had identified early in their studies, targeted different sites on the human enzymes. They used a fragment-based drug design approach to combine the two inhibitors and structure-guided design to optimize the combination agent’s drug properties.

The investigators reported in the May 14, 2018, online edition of the journal Nature Chemistry that that inhibition of the myristoylation of a specific virus-encoded protein (VP0) by IMP-1088 potently blocked a key step in viral capsid assembly, to deliver a low nanomolar antiviral activity against multiple RV strains, poliovirus, and foot and-mouth disease virus. The compound was found to be nontoxic to cell cultures.

"The common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and COPD. A drug like this could be extremely beneficial if given early in infection, and we are working on making a version that could be inhaled, so that it gets to the lungs quickly," said senior author Dr. Edward W. Tate, professor of chemical biology at Imperial College London.

Related Links:
Imperial College London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more